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Eur J Vasc Endovasc Surg (2009) 38, 533e535Explaining racial disparities in mortality after abdominal aortic aneurysm
repair
Nicholas H. Osborne, Gilbert R. Upchurch Jr, Amit K. Mathur, Justin B. Dimick
Background: Black patients have a highermortality rate than nonblacks after
abdominal aortic aneurysm repair. We sought to understand the factors
responsible for this racial disparity in themortality rate after aneurysm repair.
Methods: The Medicare database (2001-2006) was used to identify 160,785
patients undergoing open and endovascular abdominal aortic aneurysm
repairs. We used risk-adjusted mortality as our primary measure of quality
and logistic regression to determine the relationship between race and
mortality, sequentially adding contributing factors including patient charac-
teristics, the type of repair (endovascular vs open repair), socioeconomic
status, and hospital quality. From these sequential regression models, we
estimated the proportion of the disparity that can be explained by each
factor.
Results: Black patients had a 36% higher risk-adjusted mortality after aneu-
rysm repair than nonblack patients (odds ratio [OR], 1.36; 95% confidence
interval [CI], 1.20-1.53). Even after accounting for the type of repair,
a significant difference in mortality remained (OR, 1.33; 95% CI, 1.18-
1.50). Mortality rates were higher in hospitals treating a higher proportion
of black patients. Adjusting for these differences in hospital quality, this
disparity was no longer significant (OR, 1.07; 95% CI, 0.93-1.25). We estimate
that the 29% of the observed disparity in mortality is caused by patient
comorbidities, 6% from the use of endovascular repairs, 26% due to socioeco-
nomic factors, and 25% because black patients receive care in lower-quality
hospitals.
Conclusions: Although many factors contribute, a large proportion of
observed disparities in outcomes are attributable to black patients receiving
care in lower-quality hospitals. Efforts aimed at improving disparities must
focus on improved access to high-quality hospitals and improved resources
at the hospitals that treat higher proportions of black patients.
Intermediate results of a United States multicenter trial of fenestrated
endograft repair for juxtarenal abdominal aortic aneurysms
Roy K. Greenberg, W. Charles Sternbergh, Michel Makaroun, Takao Ohki,
Timothy Chuter, Priya Bharadwaj, Alan Saunders, on behalf of the
Fenestrated Investigators
Objective: This article reports the intermediate-term (24-month) outcomes
of a prospective multicenter trial designed to evaluate the Zenith Fenes-
trated AAA Endovascular Graft (Cook Medical, Bloomington, Ind) for treating
juxtarenal abdominal aortic aneurysms with short proximal necks. The study
goals were to evaluate the safety and preliminary effectiveness of the
device and refine patient selection criteria.
Methods: Five centers in the United States enrolled 30 patients with juxta-
renal aortic aneurysms with 50-mm diameter and short proximal necks.
Devices were custom-designed for each patient based on measurements from
reconstructed computed tomography (CT) data. Follow-up studies included
physical examinations, laboratory studies, CT imaging, mesenteric-renal
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doi:10.1016/S1078-5884(09)00425-0duplex ultrasound imaging, and kidneys, ureter and bladder imaging at
hospital discharge, at 1, 6, and 12months, and yearly thereafter up to 5 years.
Results: During a 1-year period, 30 patients (80% men; mean age, 75 years)
with a mean aneurysm size of 61.4 mm were enrolled. In these 30 patients,
77 visceral vessels were accommodated by fenestrations located within the
sealing segment of the grafts. The most common design accommodated two
renal arteries and the superior mesenteric artery (66.7%). All prostheses
were implanted successfully. No visceral arteries were lost. Of the 30
patients treated, 27 were available for 12-month follow-up and 23 were
available for 24-month follow-up. No aneurysm-related deaths, aneurysm
ruptures, or conversions were observed through 24 months of follow-up.
No type I or type III endoleaks were observed. Type II endoleaks were noted
in six (26.1%) at 12 months and four (20.0%) at 24 months. No patients had
aneurysm growth >5 mm. Aneurysm size decreased in 16 of 23 (69.6%) and
was stable in the remaining patients at 24 months. Eight patients experi-
enced a renal event (4 renal artery stenoses, 2 renal artery occlusions,
and 2 renal infarcts). Five underwent secondary interventions. No renal
failure developed requiring dialysis.
Conclusions: The intermediate-term (24-month) results of the 30 patients in
this multicenter study are concordant with previous single-center studies
and support the concept that placement of fenestrated endovascular grafts
is safe and effective at centers with experience in endovascular repair and
renal/mesenteric stent placement.
Perioperative asymptomatic cardiac damage after endovascular
abdominal aneurysm repair is associated with poor long-term outcome
Tamara A. Winkel, Olaf Schouten, Jan-Peter van Kuijk, Hence J.M. Verhagen,
Jeroen J. Bax, Don Poldermans
Background: Endovascular abdominal aortic aneurysm (AAA) repair (EVAR)
is associated with a decreased incidence of perioperative cardiac complica-
tions compared with open repair. However, EVAR is not associated with long-
term survival benefit. This study assessed the effect of perioperative asymp-
tomatic cardiac damage after EVAR on long-term prognosis.
Methods: In 220 patients undergoing elective EVAR, routine sampling for
levels of cardiac troponin T and electrocardiography (ECG) were performed
on days 1, 3, and 7 during the patient’s hospital stay. Elevated cardiac
troponin Twas defined as serum concentrations 0.01 ng/mL. Asymptomatic
cardiac damage was defined as cardiac troponin T release without symptoms
or ECG changes. The median follow-up was 2.9 years. Survival status was ob-
tained by contacting the Office of Civil Registry.
Results: Release of cardiac troponin T (median, 0.08 ng/ml) occurred in 24
of 220 patients, of whom 20 (83%) were asymptomatic and without ECG
changes. Patients with asymptomatic cardiac damage had a mortality rate
of 85% after 2.9 years vs 51% for patients without perioperative cardiac
damage (P < .001). Also after adjustment for clinical risk factors and medi-
cation use applying multivariate Cox regression analysis, asymptomatic
cardiac damage was associated with a 2.3-fold increased risk for death
(95% confidence interval, 1.1-5.1). Statin use was associated with a reduced
long-term risk for death (hazard ratio, 0.5; 95% confidence interval, 0.3-0.9).
Conclusion: Asymptomatic cardiac damage in patients undergoing EVAR is
associated with poor long-term outcome. Routine perioperative cardiac
screening after EVAR might be warranted.
534 AbstractsValidation of the PIII CLI risk score for the prediction of amputation-free
survival in patients undergoing infrainguinal autogenous vein bypass for
critical limb ischemia
Andres Schanzer, Philip P. Goodney, Youfu Li, Mohammad Eslami, Jack
Cronenwett, Louis Messina, Michael S. Conte, for the Vascular Study Group
of Northern New England
Objective: The PREVENT III (PIII) critical limb ischemia (CLI) risk score is
a simple, published tool derived from the PIII randomized clinical trial that
can be used for estimating amputation-free survival (AFS) in CLI patients
considered for infrainguinal bypass (IB). The current study sought to validate
this risk stratification model using data from the prospectively collected
Vascular Study Group of Northern New England (VSGNNE).
Method: We calculated the PIII CLI risk score for 1166 patients undergoing IB
with autogenous vein by 59 surgeons at 11 hospitals between January 1,
2003, and December 31, 2007. Points (pts) were assigned to each patient
for the presence of dialysis (4 pts), tissue loss (3 pts), age 75 (2 pts),
and coronary artery disease (CAD) (1 pt). Baseline hematocrit was not
included due to a large proportion of missing values. Total scores were used
to stratify each patient into low-risk (3 pts), med-risk (4-7 pts), and high-
risk (8 pts) categories. The Kaplan-Meier method was used to calculate AFS
for the three risk groups. Log-rank test was used for intergroup comparisons.
To assess validation, comparison to the PIII derivation and validation sets
was performed.
Result: Stratification of the VSGNNE patients by risk category yielded three
significantly different estimates for 1-year AFS (86.4%, 74.0%, and 56.1%, for
low-, med-, and high-risk groups). Intergroup comparison demonstrated
precise discrimination (P < .0001). For a given risk category (low, med, or
high), the 1-year AFS estimates in the VSGNNE dataset were consistent with
those observed in the previously published PIII derivation set (85.9%, 73.0%,
and 44.6%, respectively), PIII validation set (87.7%, 63.7%, and 45.0%,
respectively), and retrospective multicenter validation set (86.3%, 70.1%,
and 47.8%, respectively).
Conclusion: The PIII CLI risk score has now been both internally and exter-
nally validated by testing it against the outcomes of 3286 CLI patients who
underwent autogenous vein bypass at 94 institutions by a diverse array of
physicians (three independent cohorts of patients). This tool provides
a simple and reliable method to risk stratify CLI patients being considered
for IB. At initial consultation, calculation of the PIII CLI risk score can reliably
stratify patients according to their risk of death or major amputation at 1
year.
Infrapopliteal balloon angioplasty for the treatment of chronic occlusive
disease
Mark F. Conrad, Jeanwan Kang, Richard P. Cambria, David C. Brewster,
Michael T. Watkins, Christopher J. Kwolek, Glenn M. LaMuraglia
Objective: There is little documentation of the effectiveness of percuta-
neous balloon angioplasty (PTA) of infrapopliteal vessels for the treatment
of chronic lower extremity ischemia. This study reviewed our recent experi-
ence with infrapopliteal PTA in a large series of patients to determine its
effectiveness as a treatment modality.
Methods: All patients undergoing primary infrapopliteal PTA from March
2002 to June 2006 were included. Primary study end points were primary
patency, assisted patency, limb salvage, and patient survival assessed by
Kaplan-Meier life-table analysis. Factors predictive of PTA failure and
patient longevity were evaluated by multivariate methods.
Results: There were 155 PTAs undertaken in 144 patients (70% men; mean
age, 74 years), with critical limb ischemia (86%), diabetes (66%), and renal
insufficiency (45%). Infrapopliteal lesions were classified as TransAtlantic
Inter-Society Consensus A (7%), B (18%), C (39%), and D (35%). PTA was
confined to the infrapopliteal segment in 40 (26%), and 115 (74%) underwent
multilevel treatment. Five patients (3%) received stents. Technical success
was 95%. The 30-day mortality was 2%, and major morbidity was 3%. The
mean follow-up was 22 months (range, 0-54 months). The 40-month actu-
arial primary patency was 62% (standard error, 5%), with assisted patency
(infrapopliteal re-PTA, 25 [16%]) of 90%. Interval conversion to bypass
surgery occurred in seven (5%). Nonhealing ulcers occurred in 118 patients
(76%), of which 76 (64%) healed during follow-up. Of the 42 unhealed ulcers,
15 (13%) required major amputations for a 40-month limb salvage of 86.2%.Multivariate predictors that were negative for primary patency included 0/1
vessel runoff (P = .01), critical limb ischemia (P = .002), and dialysis (P = .03).
Negative predictors of limb salvage included dialysis (P = .007) and failure to
improve runoff to the foot (P = .006). At 40-months, patient survival was 54%,
with negative predictors including severe pulmonary disease (P = .01),
coronary artery disease (P = .04), and renal insufficiency (P < .001).
Conclusions: Infrapopliteal angioplasty can be performed safely with favor-
able results in patients with limited longevity. Primary patency is related to
disease extent. Secondary interventions may be necessary to maintain clin-
ical success. These data indicate that PTA should be considered as initial
therapy for infrapopliteal occlusive disease in patients with lower extremity
ischemia.
Restenosis after renal artery angioplasty and stenting: Incidence and risk
factors
Matthew A. Corriere, Matthew S. Edwards, Jeffrey D. Pearce, Jeanette S.
Andrews, Randolph L. Geary, Kimberley J. Hansen
Background: Management of renal artery stenosis (RAS) with primary renal
artery percutaneous angioplasty and stenting (RA-PTAS) is associated with
a low risk of periprocedural death and major complications; however, rest-
enosis develops in a subset of patients and repeat intervention may be
required. We examined the incidence of restenosis after RA-PTAS and asso-
ciations with clinical factors.
Methods: Consecutive patients undergoing RA-PTAS for hemodynamically
significant atherosclerotic RAS associated with hypertension or ischemic
nephropathy, or both, between October 2003 and September 2007 were
identified from a registry. Restenosis was defined using duplex ultrasound
(DUS) imaging as a renal artery postintervention peak systolic velocity
(PSV) 180 cm/s. The incidence and temporal distribution of restenosis
was analyzed using survival analysis based on treated kidneys. Associations
between clinical factors and recurrent stenosis were examined using propor-
tional hazards regression.
Results: RA-PTAS was performed on 112 kidneys for atherosclerotic RAS
during the study period. Initial postintervention renal artery DUS imaging
confirming PSV <180 cm/s in 101 kidneys, which formed the basis of this
analysis. Estimated restenosis-free survival was 50% at 12 months and
40% at 18 months. Decreased risk of restenosis was associated with
preoperative statin use (hazard ratio [HR], 0.35; 95% confidence interval
[CI], 0.16-0.74; P = .006) and increased preoperative diastolic blood pres-
sure (DBP; HR, 0.70 per 10-mm Hg increase in preoperative DBP; 95% CI,
0.49-0.99; P = .049). No other factors assessed were associated with
restenosis.
Conclusion: Restenosis occurs in a substantial number of patients treated
with RA-PTAS. Preoperative statin medication use and increased preopera-
tive DBP are associated with reduced risk of restenosis. In the absence of
contraindications, statins should be considered standard therapy for
patients with atherosclerotic renal artery stenosis.
Predictive factors of success following radio-frequency stylet (RFS)
ablation of incompetent perforating veins (IPV)
Anil P. Hingorani, Enrico Ascher, Natalie Marks, Alexander Shiferson, Nirav
Patel, Kapil Gopal, Theresa Jacob
Objective: To evaluate potential predictive factors associated with success
or failure of incompetent perforating veins (IPVs) treated with radio-
frequency stylet (RFS).
Methods: Over the last 12 months in this observational study, 38 consecu-
tive patients with various degrees of venous insufficiency and IPVs under-
went 48 office-based RFA procedures (1 - C 3; 7 - C 4; 10 - C 5; 30 - C 6) in
44 limbs There were 21 females and 17 males with mean age 67  17 years
(38-93 years) had a total of 93 IPVs (40 calf ; 53 ankle). Eighteen patients
(47%) had ipsilateral great saphenous vein (GSV) radio-frequency closures
performed prior to current procedure. The venous flow pattern was
classified by spectral waveform analysis as ‘‘normal’’ (spontaneous with
respiratory phasicity) in 33 patients and ‘‘pulsatile’’ (with bidirectional
cardiac phasicity) in five patients. Follow-up duplex scans were performed
from 3 to 7 days postprocedure. Statistical analyses were performed for
Abstracts 535determining correlation between the various factors such as, age, pulsa-
tile flow, CEAP class, prior GSV ablation, vein diameter, reflux, and
patency.
Results: The mean number of ablated IPVs was 1.94  0.38 ranging from1-3.
Immediate success rate was 88% (82 cases, 32 patients). IPVs had a duplex
measured mean diameter of 3.8  1.1 mm (2-6.6 mm). Eleven IPVs remained
patent in six patients. There was no significant difference between thepatent and the obliterated IPV groups concerning age (P = 0.75), prior GSV
ablation (P = .19), IPV diameter (P = .08) and CEAP classification. Conversely,
four of the five procedures (80%) performed in patients with ‘‘pulsatile’’
venous flow failed while only two of the remaining 43 procedures (4.7%) in
patients with ‘‘normal’’ venous flow failed (P < .001).
Conclusion: These data show that a pulsatile venous flow pattern is a signif-
icant predictor of failure following RFS for IPVs.
